A prospective randomized study comparing drug efficacy of tibolone, conjugated equine estrogen, combined estrogen and progesterone for symptomatic relief in postmenopausal women
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20263030Keywords:
Conjugated equine estrogen, Combined estrogen-progesterone, Postmenopausal, TiboloneAbstract
Background: Menopause is linked to various vasomotor, psychological, and urogenital symptoms that greatly impact quality of life. Menopausal hormone therapy (MHT), such as tibolone, conjugated equine estrogen (CEE), and combined estrogen-progesterone treatments, is commonly used to alleviate these symptoms. Nevertheless, comparative data regarding their efficacy and safety remain limited.
Methods: This prospective randomized controlled trial involved 99 postmenopausal women aged between 45-65 years, divided into three groups: tibolone, CEE, and combined estrogen-progesterone (33 participants each). The severity of symptoms was measured at baseline, 3 months, and 6 months. Adverse effects and treatment tolerability were also evaluated. Statistical analysis was performed using SPSS software with significance set at p<0.05.
Results: Baseline symptom severity was similar across all groups, with the majority of participants having mild to moderate symptoms. Mean symptom scores stayed mostly consistent at 3 and 6 months in all groups, showing no statistically significant difference in overall symptom improvement. However, the occurrence of side effects differed between groups. Tibolone had the lowest rates of breast tenderness and vaginal bleeding, whereas CEE and combined therapy were associated with higher rates of these side effects.
Conclusions: While all three treatments showed similar effectiveness in managing overall symptoms, tibolone had a better safety profile. These results emphasize the importance of individualized treatment selection based on patient characteristics, symptoms, and tolerability.
References
Research on the menopause in the 1990s. Report of a WHO Scientific Group. World Health Organ Tech Rep Ser. 1996;866:1-107.
Panay N, Fenton A, Hamoda H, Hillard T, Islam RM, Pedder H, et al. IMS Recommendations Writing Group. International Menopause Society recommendations and key messages on women’s midlife health and menopause. Climacteric. 2025;28(6):634-56.
Berek JS, Berek DL. Berek and Novak’s Gynecology, 16e. Lippincott Williams and Wilkins, a Wolters Kluwer business; 2020.
Fritz MA, Speroff L. Clinical Gynecologic Endocrinology and Infertility. Lippincott Williams and Wilkins; 2011.
“The 2022 Hormone Therapy Position Statement of The North American Menopause Society” Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767-794.
Formoso G, Perrone E, Maltoni S, Balduzzi S, Wilkinson J, Basevi V, et al. Short-term and long-term effects of tibolone in postmenopausal women. Cochrane Database Syst Rev. 2016;10(10):CD008536.
Modelska K, Cummings S. Tibolone for postmenopausal women: systematic review of randomized trials. J Clin Endocrinol Metab. 2002;87(1):16-23.
Lobo RA. Benefits and risks of estrogen replacement therapy. Am J Obstet Gynecol. 1995;173(3 Pt 2):982-9.
Archer DF. Endometrial bleeding during hormone therapy: the effect of progestogens. Maturitas. 2007;57(1):71-6.
Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. writing group for the women’s health initiative investigators. risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women’s health initiative randomized controlled trial. JAMA. 2002;288(3):321-33.
Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, et al. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA. 2004;291(14):1701-12.
Davis SR, Lambrinoudaki I, Lumsden M, Mishra GD, Pal L, Rees M, et al. Menopause. Nat Rev Dis Primers. 2015;1:15004.
Archer DF, Pinkerton JV, Utian WH. Menopausal hormone therapy and uterine bleeding. Menopause. 2010;17(5):978-84.
Cummings SR, Ensrud K, Delmas PD, LaCroix AZ, Vukicevic S, Reid DM, et al. Study Investigators. Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med. 2010;362(8):686-96.
Maclennan AH, Broadbent JL, Lester S, Moore V. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev. 2004;2004(4):CD002978.
Nelson HD, Walker M, Zakher B, Mitchell J, Weber RP, Stuenkel CA. Menopausal hormone therapy for the primary prevention of chronic conditions: a systematic review to update the U.S. preventive services task force recommendations. Ann Intern Med. 2017;167(3):165-78.
Chen LR, Chen KH. Utilization of isoflavones in soybeans for women with menopausal syndrome: an overview. Int J Mol Sci. 2021;22(6):3212.
Davis SR. The effects of tibolone on mood and libido. Menopause. 2002;9(3):162-70.
Moyer VA. US Preventive Services Task Force. Menopausal hormone therapy for the primary prevention of chronic conditions: US Preventive services task force recommendation statement. Ann Intern Med. 2013;158(1):47-54.
Baker FC, Lampio L, Saaresranta T, Polo-Kantola P. Sleep and sleep disorders in the menopausal transition. Sleep Med Clin. 2018;13(3):443-56.
Kronenberg F. Hot flashes: epidemiology and physiology. Ann N Y Acad Sci. 1990;592:52-86;123-33.
Levine S, Green G, Polotsky A. Menopause and aging: changes and challenges. Clin Obstet Gynecol. 2018;61(3):508-16.
Downloads
Published
How to Cite
Issue
Section
